Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol Sulphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
London Research Presents LRP-661, their Oral Cannabidiol Sulphate Candidate
Details : LRP-661 or cannabidiol sulphate (CBDS), an orally available and improved formulation of cannabidiol (CBD), being developed for seizures associated with severe childhood epilepsy syndromes.
Product Name : LRP-661
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Cannabidiol Sulphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable